ES2540255A1 - Método de aislamiento de cuerpos apoptóticos - Google Patents

Método de aislamiento de cuerpos apoptóticos Download PDF

Info

Publication number
ES2540255A1
ES2540255A1 ES201331688A ES201331688A ES2540255A1 ES 2540255 A1 ES2540255 A1 ES 2540255A1 ES 201331688 A ES201331688 A ES 201331688A ES 201331688 A ES201331688 A ES 201331688A ES 2540255 A1 ES2540255 A1 ES 2540255A1
Authority
ES
Spain
Prior art keywords
isolation
apoptotic bodies
translation
machine
legally binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201331688A
Other languages
English (en)
Other versions
ES2540255B1 (es
Inventor
Tomás SEGURA MARTÍN
Óscar AYO MARTÍN
Gema SERRANO DE LAS HERAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to ES201331688A priority Critical patent/ES2540255B1/es
Priority to PCT/ES2014/070844 priority patent/WO2015075288A1/es
Priority to US15/037,301 priority patent/US9989521B2/en
Priority to EP14864567.4A priority patent/EP3072959B1/en
Publication of ES2540255A1 publication Critical patent/ES2540255A1/es
Application granted granted Critical
Publication of ES2540255B1 publication Critical patent/ES2540255B1/es
Priority to HK16112442.1A priority patent/HK1224328A1/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Abstract

Método de aislamiento de cuerpos apoptóticos. La presente invención pertenece al campo del estudio de la apoptosis, en particular al campo del pronóstico y monitorización de enfermedades que cursan con apoptosis. En concreto, se refiere a un método de aislamiento de cuerpos apoptótitos a partir de una muestra de fluido corporal y a métodos de pronóstico y de evaluación de la eficacia de un tratamiento de enfermedades vasculares, neurodegenerativas y/u oncológicas, basados en la utilización de dicho método de aislamiento de cuerpos apoptóticos.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26

Claims (1)

  1. imagen1
    imagen2
    imagen3
ES201331688A 2013-11-19 2013-11-19 Método de aislamiento de cuerpos apoptóticos Active ES2540255B1 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES201331688A ES2540255B1 (es) 2013-11-19 2013-11-19 Método de aislamiento de cuerpos apoptóticos
PCT/ES2014/070844 WO2015075288A1 (es) 2013-11-19 2014-11-14 Método de aislamiento de cuerpos apoptóticos
US15/037,301 US9989521B2 (en) 2013-11-19 2014-11-14 Method for isolating apoptotic bodies
EP14864567.4A EP3072959B1 (en) 2013-11-19 2014-11-14 Method for isolating apoptotic bodies
HK16112442.1A HK1224328A1 (zh) 2013-11-19 2016-10-28 分離凋亡細胞體的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201331688A ES2540255B1 (es) 2013-11-19 2013-11-19 Método de aislamiento de cuerpos apoptóticos

Publications (2)

Publication Number Publication Date
ES2540255A1 true ES2540255A1 (es) 2015-07-09
ES2540255B1 ES2540255B1 (es) 2016-05-12

Family

ID=53179011

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201331688A Active ES2540255B1 (es) 2013-11-19 2013-11-19 Método de aislamiento de cuerpos apoptóticos

Country Status (5)

Country Link
US (1) US9989521B2 (es)
EP (1) EP3072959B1 (es)
ES (1) ES2540255B1 (es)
HK (1) HK1224328A1 (es)
WO (1) WO2015075288A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3464639A4 (en) * 2016-05-31 2020-01-01 Goetzl, Edward, J. DIAGNOSTIC METHOD AND METHOD FOR TESTING THE EFFECTIVENESS OF A MEDICINAL PRODUCT FOR DEMENTIA USING ASTROCYTE-DERIVED EXOSOMES
US11612618B2 (en) 2017-11-14 2023-03-28 Henry Ford Health System Compositions for use in the treatment and prevention of cardiovascular disorders resulting from cerebrovascular injury
US20200341011A1 (en) * 2017-11-17 2020-10-29 Edward J. Goetzl Astrocyte exosome complement-based assay for neuroinflammation in alzheimer's disease and uses thereof
GB201810571D0 (en) 2018-06-27 2018-08-15 Cs Genetics Ltd Reagents and methods for the analysis of circulating microparticles
CN110029088B (zh) * 2019-04-15 2021-03-19 中山大学 肿瘤细胞凋亡小体及其制备方法和应用
GB201909325D0 (en) 2019-06-28 2019-08-14 Cs Genetics Ltd Reagents and methods for analysis for microparticles
AU2022295136A1 (en) 2021-06-18 2024-01-18 Cs Genetics Limited Reagents and methods for molecular barcoding

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154689A1 (en) * 2010-06-07 2011-12-15 King's College London Methods and means for predicting or diagnosing diabetes or cardiovascular disorders based on micro rna detection
WO2013164289A1 (en) * 2012-04-30 2013-11-07 Imcyse Sa Methods for induction of antigen-specific regulatory t cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058645A1 (en) 1998-05-11 1999-11-18 I.N.S.E.R.M. (Institut National de la Santé et de la Recherche Médicale) New apoptotic bodies, monocyte derived cells containing the same, a process for their preparation and their uses as vaccines
US20050266405A1 (en) 2002-03-08 2005-12-01 Kopreski Michael S Analysis of apoptotic bodies in bodily fluids
WO2011100458A2 (en) * 2010-02-10 2011-08-18 Bioo Scientific Corporation Methods for fractionating and processing microparticles from biological samples and using them for biomarker discovery
WO2012110253A2 (en) * 2011-02-18 2012-08-23 Cavadis B.V. Exosomal biomarkers for cardiovascular events

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154689A1 (en) * 2010-06-07 2011-12-15 King's College London Methods and means for predicting or diagnosing diabetes or cardiovascular disorders based on micro rna detection
WO2013164289A1 (en) * 2012-04-30 2013-11-07 Imcyse Sa Methods for induction of antigen-specific regulatory t cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CRESCITELLI, A., et al. Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes.Journal of extracellular vesicles Sweden. 12/09/2012 VOL: 2 Pags: 20677 ISSN 2001-3078 (Electrónico) Doi: 10.3402/jev.v2i0.20677 pubmed:24223256. Ver Resumen, Introducción y apartados 1 y 2 de Materiales y métodos. *
ELLIOTT, D. A. et al. Apoptosis induces neuronal apolipoprotein-E synthesis and localization in apoptotic bodies. Neuroscience letters Ireland 12/04/2007 VOL: 416 No: 2 Pags: 206 - 210 ISSN 0304-3940 (Impreso) Doi: pubmed:17320289. Ver todo el documento. *
HOLTOM, E. et al. Microparticle formation after co-culture of human whole blood and umbilical artery in a novel in vitro model of flow. Cytometry. Part A : the journal of the International Society for Analytical Cytology United States May 2012 00/05/2012 VOL: 81 No: 5 Pags: 390 - 399 ISSN 1552-4930 (Electrónico) Doi: doi:10.1002/cyto.a.22010 pubmed:22213485. Ver todo el documento. *

Also Published As

Publication number Publication date
EP3072959B1 (en) 2018-03-21
HK1224328A1 (zh) 2017-08-18
WO2015075288A1 (es) 2015-05-28
ES2540255B1 (es) 2016-05-12
US20160290996A1 (en) 2016-10-06
US9989521B2 (en) 2018-06-05
EP3072959A4 (en) 2016-09-28
EP3072959A1 (en) 2016-09-28

Similar Documents

Publication Publication Date Title
ES2540255A1 (es) Método de aislamiento de cuerpos apoptóticos
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201892635A1 (ru) Иммуномодуляторы для пэт-визуализации
DK3043718T3 (da) Biologisk fluidfiltreringsanordning
FR3001211B1 (fr) Dispositif de traitement de liquide
DK3107899T3 (da) Mitokondriel aldehyddehydrogenase 2 (aldh2)-bindende polycykliske amider og anvendelse deraf til cancerbehandling
CL2018001275A1 (es) Sistema de detección electroquímica de moléculas de interés
BR112016016816A2 (pt) dispositivo de processamento de meio e dispositivo de transação de meio
EP3422198A4 (en) MULTI-CHIP MULTIPROCESSOR COOPERATION COHERENCE OPERATING METHOD AND MULTI-CHIP MULTIPROCESSOR
DK2988760T3 (da) C. novyi til behandlingen af faste tumorer i mennesker
FR3025792B1 (fr) Dispositif de traitement d'effluents salins sursatures en presence d'inhibiteurs de precipitation
BR112016016618A2 (pt) dispositivo de processamento de meio e dispositivo de transação de meio
BR112017005252A2 (pt) método para detecção de molécula alvo e kit para utilização no referido método.
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
CL2015001936A1 (es) Composición y su uso que sirve para preparar un medicamento útil para tratar enfermedades relacionadas con el factor inducible por hipoxia (hif).
BR112017002513A2 (pt) sequestrantes de aldeído e métodos para fabricação e uso dos mesmos
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
EA201591304A1 (ru) Применение комплекса, облегчающего транскрипцию хроматина (fact), при раке
BR112016004450A2 (pt) métodos para tratar uma doença, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir desenvolvimento da reincidência e/ou resistência de uma doença, para aumentar a sensibilidade a um inibidor, para estender o período de sensibilidade a um inibidor e para estender a duração de resposta a um inibidor
BR112017013154A2 (pt) método para o monitoramento da evolução de um indicador usado para indicar o estado físico de um indivíduo, e dispositivo de monitoramento.
IT201600109735A1 (it) Biomarcatori e metodi per la diagnosi in vitro di sclerosi multipla.
IT201600069927A1 (it) Metodo per la diagnosi in vitro di carcinoma tiroideo.
FR3028858B1 (fr) Anticorps monoclonal specifique de borrelia crocidurae et une methode de diagnostic in vitro d'une fievre recurrente de borreliose
CY1119998T1 (el) Παραγοντας ανοσο-απεικονισης για χρηση στην θεραπεια με συζευγμα αντισωματος-φαρμακου
CY1119986T1 (el) Παραγοντας ανοσο-απεικονισης για χρηση στην θεραπεια με συζευγμα αντισωματος-φαρμακου

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2540255

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20160512